Advance Search
ZHANG Sanhong. Effect observation of early application of low molecular weight heparin calcium in prevention of coagulation dysfunction in patients with respiratory failure[J]. Journal of Clinical Medicine in Practice, 2019, 23(21): 58-60. DOI: 10.7619/jcmp.201921017
Citation: ZHANG Sanhong. Effect observation of early application of low molecular weight heparin calcium in prevention of coagulation dysfunction in patients with respiratory failure[J]. Journal of Clinical Medicine in Practice, 2019, 23(21): 58-60. DOI: 10.7619/jcmp.201921017
shu

Effect observation of early application of low molecular weight heparin calcium in prevention of coagulation dysfunction in patients with respiratory failure

More Information
  • Received Date: August 10, 2019
  • Accepted Date: September 27, 2019
  • Available Online: February 28, 2021
  • Published Date: November 14, 2019
    Graphical Abstract
    • Abstract
  •   Objective  To explore the effect of early application of low molecular weight heparin calcium on the prevention of coagulation dysfunction in patients with respiratory failure.
      Methods  A total of 92 patients with respiratory failure were randomly divided into two groups, with 46 cases in each group. The patients in both groups were given regular treatment, such as cough relief, expectoration, asthma relief, mechanical ventilation and low flow oxygen inhalation. On this basis, the study group was given hypodermic injection of low molecular weight heparin calcium. The blood gas analysis indexes before and after treatment were compared between two groups, including pH value, partial pressure of arterial carbon dioxide[p(CO2)] and partial pressure of arterial blood oxygen[p(O2)]. The coagulation function including partial thromboplastin time (APTT), prothrombin time (PT), D-Dimer (D-D), platelet (PLT) of the two groups before and after treatment was compared.
      Results  After treatment, the pH, p(CO2) and p(O2) levels of the two groups significantly improved, and the pH, p(CO2) and p(O2) levels of the study group were significantly higher than those of the control group (P < 0.05). After treatment, APTT, PT, D-D and PLT in both groups significantly improved when compared with those before treatment, and APTT, PT, D-D and PLT in the study group were significantly better than those in the control group (P < 0.05).
      Conclusion  Early application of low molecular weight heparin calcium is effective and safe in the treatment of respiratory failure, which can improve the coagulation function and blood gas indexes, reduce the rate of thrombosis, and promote the improvement of disease condition.
    • FullText(HTML)
    • References (23)
  • [1]
    张润娟. 慢性阻塞性肺疾病急性加重期治疗中低分子肝素早期干预价值评估[J]. 中国医药科学, 2018, 8(10): 33-35. doi: 10.3969/j.issn.2095-0616.2018.10.011
    [2]
    何智群, 毛永毅. 慢性阻塞性肺疾病急性加重期治疗中低分子肝素早期干预效果探讨[J]. 国际呼吸杂志, 2015(15): 1152-1154. doi: 10.3760/cma.j.issn.1673-436X.2015.15.009
    [3]
    陈洪江, 李志丹. 肺心病合并呼吸衰竭患者凝血功能及心电图的变化特点及临床治疗分析[J]. 中外医学研究, 2018, 16(3): 50-52. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY201803027.htm
    [4]
    甘畅新. 低分子肝素钙治疗肺心病合并呼吸衰竭的临床疗效[J]. 世界临床医学, 2016, 16(9): 5-8. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYZ202002010.htm
    [5]
    高俊耀. 低分子肝素钙治疗肺心病合并呼吸衰竭的临床分析[J]. 中国卫生标准管理, 2016, 7(5): 80-82. https://www.cnki.com.cn/Article/CJFDTOTAL-WSBZ201605061.htm
    [6]
    张静, 杨芳, 张川, 等. NCPAP联合低分子肝素对重症肺炎患者肺功能和血氧饱和度的影响[J]. 解放军预防医学杂志, 2018, 36(10): 1277-1279, 1282. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYX201810015.htm
    [7]
    罗姝. 低分子肝素钙早期干预防治呼吸衰竭患者凝血功能异常的临床研究[J]. 湖南师范大学学报: 医学版, 2016, 13(6): 119-122. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYG201606041.htm
    [8]
    郎红娟. 低分子肝素钙治疗肺心病合并呼吸衰竭的临床研究[J]. 中国卫生标准管理, 2015, 6(7): 173-174. https://www.cnki.com.cn/Article/CJFDTOTAL-WSBZ201507139.htm
    [9]
    赵罗亚, 卢生芳. 低分子肝素在慢性阻塞性肺疾病急性加重期合并呼吸衰竭患者的疗效观察[J]. 贵州医药, 2016, 40(5): 482-483. doi: 10.3969/j.issn.1000-744X.2016.05.014
    [10]
    吐尔逊·尼亚孜. 慢性阻塞性肺疾病急性加重期治疗中低分子肝素早期干预价值分析[J]. 中国继续医学教育, 2018, 10(17): 124-125. doi: 10.3969/j.issn.1674-9308.2018.17.061
    [11]
    沈威, 翁婷, 高蔚. 早期应用低分子肝素对慢性阻塞性肺疾病急性加重期的影响[J]. 临床肺科杂志, 2016, 21(12): 2274-2276. doi: 10.3969/j.issn.1009-6663.2016.12.040
    [12]
    王玉婷, 余霓雯. 低分子肝素对AECOPD合并呼吸衰竭患者凝血功能及血清TNF-α、CK-MB、CRP水平的影响[J]. 海南医学院学报, 2017, 23(4): 478-481. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYY201704013.htm
    [13]
    邓锐. 低分子肝素治疗对AECOPD患者肺功能和凝血功能的影响[J]. 海南医学院学报, 2016, 22(13): 1377-1379, 1382. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYY201613014.htm
    [14]
    曾建红, 曾军, 李越利, 等. 低分子肝素在慢性阻塞性肺疾病急性加重期合并呼吸衰竭的治疗作用[J]. 中国医药科学, 2016, 6(14): 46-48, 51. https://www.cnki.com.cn/Article/CJFDTOTAL-GYKX201614013.htm
    [15]
    冯慧萍. 低分子肝素对慢性阻塞性肺疾病患者的疗效[J]. 包头医学院学报, 2016, 32(5): 46-48. https://www.cnki.com.cn/Article/CJFDTOTAL-BTYX201605025.htm
    [16]
    孔民, 高亮. 低分子肝素钙早期干预防治呼吸衰竭患者凝血功能异常的临床研究[J]. 系统医学, 2018(13): 41-42, 46. https://www.cnki.com.cn/Article/CJFDTOTAL-XTYX201813016.htm
    [17]
    李丁. 探讨低分子肝素钙治疗肺心病并呼吸衰竭的临床疗效[J]. 中国现代药物应用, 2017, 11(9): 119-120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY201709061.htm
    [18]
    顾毅. 低分子肝素钙治疗肺心病合并呼吸衰竭患者的临床效果[J]. 心理月刊, 2019(5): 126-126. https://www.cnki.com.cn/Article/CJFDTOTAL-XLYK201905120.htm
    [19]
    屈占德. 低分子肝素钙治疗肺心病并呼吸衰竭临床观察[J]. 中国实用医药, 2019, 14(3): 80-81. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201903047.htm
    [20]
    李喆, 朱应群, 何龙培, 等. 低分子肝素钙治疗肺心病合并呼吸衰竭患者的临床效果[J]. 国际医药卫生导报, 2016, 22(12): 1731-1733. doi: 10.3760/cma.j.issn.1007-1245.2016.12.022
    [21]
    杨维荣. 低分子肝素钙治疗肺心病合并呼吸衰竭患者的临床效果[J]. 家庭医药. 就医选药, 2017(9): 90-91. https://www.cnki.com.cn/Article/CJFDTOTAL-YYJT201709105.htm
    [22]
    宋学坤, 杨松涛. 用低分子肝素联合丹红注射液治疗肺心病呼吸衰竭的疗效观察[J]. 求医问药: 下半月, 2013, 11(7): 78-79. https://www.cnki.com.cn/Article/CJFDTOTAL-QYWA201307081.htm
    [23]
    周茜. 用低分子肝素钙治疗肺源性心脏病并发呼吸衰竭的效果探讨[J]. 当代医药论丛, 2019, 17(10): 174-175. doi: 10.3969/j.issn.2095-7629.2019.10.126
    • Related Articles

  • Related Articles

    [1]GONG Yujia, LI Hailong, CAO Hui. Mechanism of circ-001209 on retinal angiogenesis in rats with diabetic retinopathy by regulating interleukin-33/suppression of tumorigenicity 2 signaling pathway[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 23-18, 33. DOI: 10.7619/jcmp.20243144
    [2]BIAN Yun, BAI Hailong, MENG Xiaofeng, LIU Xiao, XUE Chao, LIU Ruixue, CHANG Hongkun, TIAN Fengsheng, CUI Ronggang, SU Yang, LIU mei. Analysis of network pharmacological mechanism of Zhenlian Mingmu Capsule in treatment of diabetic retinopathy[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 75-82. DOI: 10.7619/jcmp.20232153
    [3]ZUO Shufei, LIANG Shu, QIN Yilu, WU Jie, ZHANG Chao, GUO Zhanfei, BIAN Caiyue, FAN Wenqiang. Effect and mechanism of mircoRNA-6779-5p on chondrocyte injury induced by interleukin-1β[J]. Journal of Clinical Medicine in Practice, 2023, 27(12): 69-75, 79. DOI: 10.7619/jcmp.20231173
    [4]PANG Hanqing, SHANG Xiaoyu, WEI Ye, DING Shuwen, LIU Liang. Mechanism of Tongmai granules in treatment of stroke based on ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry and network pharmacology[J]. Journal of Clinical Medicine in Practice, 2022, 26(24): 13-19. DOI: 10.7619/jcmp.20223482
    [5]WEI Yu, XU Xuefeng, TANG Xiaojun, LIANG Jun, FENG Xuebing, ZHAO Cheng. Role and mechanism of developmental endothelial locus-1 in collagen-induced arthritis[J]. Journal of Clinical Medicine in Practice, 2022, 26(17): 53-56. DOI: 10.7619/jcmp.20220543
    [6]LI Wenji, HU Fang, XU Wei. Mechanism of Chuanlong Anti-cancer Decoction in treatment of prostate cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(5): 18-23. DOI: 10.7619/jcmp.20214121
    [7]JIN Xuening, LIN Fei, FENG Xinyi, LI Cen, CUI Shu′na. Mechanism of docetaxel in treatment of choriocarcinoma based on network pharmacology[J]. Journal of Clinical Medicine in Practice, 2022, 26(1): 18-21. DOI: 10.7619/jcmp.20213494
    [8]QIN Wei, YIN Zixin, HUA Weiwei, WANG Yujie, WANG Yang, DENG Jialin, CAI Zhaoying, QIAN Yayun. Mechanisms of Marsdenia tenacissima in inhibiting gastric cancer based on network pharmacologyand molecular docking technology[J]. Journal of Clinical Medicine in Practice, 2022, 26(1): 1-7,17. DOI: 10.7619/jcmp.20213297
    [9]SHEN Jing, HUANG Wenjun, NIU Lijian, MA Yongxiang, ZHANG Jing. Research on mechanism of exercise rehabilitation therapy in cardiovascular diseases[J]. Journal of Clinical Medicine in Practice, 2021, 25(15): 124-127. DOI: 10.7619/jcmp.20211454
    [10]WANG Lei, CHEN Kun. Analysis in mechanism of Taohong Siwu Decoction in the treatment of femoral head necrosis based on network pharmacology[J]. Journal of Clinical Medicine in Practice, 2021, 25(2): 10-15,19. DOI: 10.7619/jcmp.20200915

  • Cited by

    Periodical cited type(9)

    1. 张丹. 闭合性胫骨远端关节外骨折的内固定术联合抗凝药物对患者患肢功能影响. 江西医药. 2023(06): 690-692+703 .
    2. 王禹，李东光，王洪淼，刘剑，邢武军. 锁定加压钢板结合MIPPO技术治疗胫骨远端骨折的优良率及对愈合时间、负重时间、bFGF、BMP-2水平的影响. 中国医学创新. 2022(09): 139-144 .
    3. 林先禄. 切开复位内固定、MIPPO技术结合LCP钢板内固定治疗胫骨远端闭合性骨折的临床研究. 实用中西医结合临床. 2022(16): 103-106 .
    4. 景晨光，杨虎. MIPPO技术结合锁定加压钢板对A型闭合性胫骨远端骨折患者踝关节功能及活动范围的影响. 临床医学研究与实践. 2021(02): 81-83 .
    5. 陈松涛. MIPPO技术结合锁定加压钢板治疗胫骨远端骨折临床疗效分析. 微量元素与健康研究. 2021(02): 78-80 .
    6. 李涛. 两种内固定对AO分型43-A型胫骨骨折的治疗效果评价. 中国卫生标准管理. 2021(17): 52-55 .
    7. 郑义海，向明，汪爱兰，江有华，袁梦龙. 无X线透视下微创切口+内侧经皮锁定钢板治疗胫骨下段螺旋型骨折的临床效果. 医学信息. 2021(23): 69-72 .
    8. 万春根，殷伟根，奚伟伟. 外侧锁定加压钢板治疗闭合性胫骨下端骨折的效果. 医学信息. 2020(08): 133-134 .
    9. 高世龙. 经皮微创锁定加压钢板内固定术治疗胫骨远端骨折患者的有效性及安全性分析. 当代医学. 2020(20): 52-55 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (334) PDF downloads (3) Cited by(10)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return